A former CEO and director of InVentiv Health, Terrell (Terry) Herring assumed the role of president of Mission Pharmacal Company in 2010. The following year, Terrell Herring also began serving as president of Alamo Pharma Services, a recruitment and talent acquisition company specializing in the pharmaceutical and biotech sector.
In February 2017, Alamo announced a partnership with Napo Pharmaceuticals, Inc., to create a national sales team for the company's new FDA-approved drug Mytesi, which provides relief from noninfectious diarrhea in people with HIV who are on antiretroviral therapies. Napo Pharmaceuticals and its partner company, Jaguar Animal Health, Inc., estimate a potential U.S. market value of more than $100 million in annual sales for the drug, and Alamo will significantly help them reach that target. Mytesi's active pharmaceutical ingredient is crofelemer, an anti-secretory agent harvested from the rain forest. The twice-daily tablets yielded encouraging results in clinical trials with HIV-positive patients, showing a reduction in the average number of watery stools per week from 20 to less than two.
0 Comments
Leave a Reply. |
AuthorTerrell Herring began working at Mission Pharmacal Company in 2010, bringing more than 25 years of experience in the pharmaceutical industry to his role as President of Commercial Operations. Archives
February 2018
Categories
All
|